| |
CRC group N=68 |
Control group N=38 |
p |
| Age (years), mean ± SD |
64.89 [55.93; 75.73] |
61.43[52.18; 66.36] |
0.604* |
| Male, n (%) |
40 (59) |
23 (61) |
1° |
| Tumor (T) stage |
| pT1 |
4 (6) |
|
|
| pT2 |
10 (15) |
|
|
| pT3 |
38 (58) |
|
|
| pT4 |
14 (21) |
|
|
| Nodal (N) stage |
| N0 |
33 (51) |
|
|
| N1 |
17 (26) |
|
|
| N2 |
15 (23) |
|
|
| Metastatic |
| M0 |
47 (72) |
|
|
| M1 |
18 (28) |
|
|
| VELIPI |
| Vascular emboli |
12 (19) |
|
|
| Lymphatic invasion |
29 (45) |
|
|
| Perineural invasion |
18 (28) |
|
|
| MSI-H |
5 (9) |
|
|
| Stenosis |
31 (47) |
|
|
|
|
| Continuous data are expressed as median [first quartile; third quartile], categorical data expressed as number (%) otherwise specify.*Wilcoxon rank sum test; °Fisher’s exact test |
| Table 1: Patients’ characteristics. |
